🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Ana Florea

Kaiser Permanente

ORCID: 0000-0003-0030-8737

Also affiliated with SimulConsult

MedicineSocial Sciences

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 1%percentile
11.0Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Interim Estimates of 2021–22 Seasonal Influenza Vaccine Effectiveness — United States, February 2022

MMWR Morbidity and Mortality Weekly Report(2022)10.15585/mmwr.mm7110a1
Top 1%
11.0DataRank
Top 1%116 citations

Sara Kim, Rebecca Kondor, Catherine M. Smith, Alicia Budd, Sara Y. Tartof +24 more

Papers

Driven by 8 papers — median percentile 99. Top paper: “Interim Estimates of 2021–22 Seasonal Influenza Vaccine Effectiveness — United States, February 2022”.

Interim Estimates of 2021–22 Seasonal Influenza Vaccine Effectiveness — United States, February 2022

MMWR Morbidity and Mortality Weekly Report(2022)10.15585/mmwr.mm7110a1
Top 1%
11.0DataRank
Top 1%116 citations

Sara Kim, Rebecca Kondor, Catherine M. Smith, Alicia Budd, Sara Y. Tartof +24 more

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants

Nature Medicine(2022)10.1038/s41591-022-01753-y
N/A
0.949DataRank · unranked
560 citations

Bradley K. Ackerson, Yi Luo, Lina S. Sy, Carla A. Talarico, Yun Tian +10 more

Impact of California’s Senate Bill 27 on Antimicrobial-Resistant Escherichia coli Urinary Tract Infection in Humans: Protocol for a Study of Methods and Baseline Data

JMIR Research Protocols(2023)10.2196/45109
N/A
0.208DataRank · unranked
3 citations

Joan A. Casey, Keeve E. Nachman, Lance B. Price, Magdalena E Pomichowski, Harpreet S. Takhar +13 more

Effectiveness of two and three mRNA COVID‐19 vaccine doses against Omicron‐ and Delta‐Related outpatient illness among adults, October 2021–February 2022

Influenza and Other Respiratory Viruses(2022)10.1111/irv.13029
N/A
0DataRank · unranked
24 citations

Jessie R. Chung, H. Keipp Talbot, Carlos G. Grijalva, Karen J. Wernli, Erika Kiniry +16 more

Effectiveness of 2 and 3 mRNA COVID-19 Vaccines Doses against Omicron and Delta-Related Outpatient Illness among Adults, October 2021 – February 2022

medRxiv(2022)10.1101/2022.04.06.22273535
N/A
0DataRank · unranked
1 citations

Jessie R. Chung, H. Keipp Talbot, Carlos G. Grijalva, Karen J. Wernli, Erika Kiniry +16 more

Work Attendance with Acute Respiratory Illness Before and During COVID-19 Pandemic, United States, 2018–2022

Emerging infectious diseases(2023)10.3201/eid2912.231070
N/A
0DataRank · unranked
3 citations

Mary Patricia Nowalk, Richard K. Zimmerman, Todd Bear, Carlos G. Grijalva, H. Keipp Talbot +14 more

Work Attendance during Acute Respiratory Illness Before and During the COVID-19 Pandemic, United States, 2018–2022

medRxiv(2023)10.1101/2023.08.03.23293611
N/A
0DataRank · unranked
0 citations

Mary Patricia Nowalk, Richard K. Zimmerman, Todd Bear, Carlos G. Grijalva, H. Keipp Talbot +14 more

Influenza Vaccine Effectiveness Against Influenza A(H3N2)-Related Illness in the United States During the 2021–2022 Influenza Season

Clinical Infectious Diseases(2022)10.1093/cid/ciac941
N/A
0DataRank · unranked
60 citations

Brendan Flannery, H. Keipp Talbot, Carlos G. Grijalva, Karen J. Wernli, C. Hallie Phillips +15 more